Role of sentinel surveillance of candidemia: Trends in species distribution and antifungal susceptibility

Journal of Clinical Microbiology

Volumn 40, Issue 10, 2002, Pages 3551-3557

  Pfaller, Michael ^a   Diekema, D J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; CANDIDIASIS; HEALTH SURVEY; NONHUMAN; PRIORITY JOURNAL; SENTINEL LYMPH NODE; SHORT SURVEY; SPECIES DISTRIBUTION;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FUNGEMIA; HUMANS; MICROBIAL SENSITIVITY TESTS; SENTINEL SURVEILLANCE;

ASPERGILLUS; FUNGI;

EID: 0036792188     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.40.10.3551-3557.2002     Document Type: Short Survey

References (66)

1. Ainscough, S., R. Barnes, V. Gant, W. R. Gransden, R. Holliman, B. McCrae, J. Perry, J. Wilson, S. Schelenz, and C. C. Kibbler. 2000. Blood stream infections due to Candida species in England and Wales. Data from ECMM epidemiological survey of candidemia in Europe. Rev. Iberoam. Micol. 17:S143.
2. American Society for Microbiology. 1995. Report of the ASM Task Force on antibiotic resistance. Antimicrob. Agents Chemother. Suppl., p. 1-23. ASM Press, Washington, D.C.
3. Arathoon, E. G., E. Gotuzzo, L. M. Noriega, R. S. Berman, M. J. DiNubile, and C. A. Sable. 2002. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. 46:451-457.
4. Blumberg, H. M., W. R. Jarvis, J. M. Soucie, J. E. Edwards, J. E. Patterson, M. A. Pfaller, M. S. Rangel-Frausto, M. G. Rinaldi, L. Saiman, R. T. Wiblin, R. P. Wenzel, and the NEMIS Study Group. 2001. Risk factors for candidal blood stream infections in surgical intensive care unit patients: the NEMIS Prospective Multicenter Study. Clin. Infect. Dis. 33:177-186.
5. Bulmer, G. S., M. L. Marquez, L. Co-Barcelona, and R. A. Fromtling. 1999. Yeasts and fluconazole susceptibility in the Philippines. Mycopathologia 146:117-120.
6. Centers for Disease Control and Prevention. 1999. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1990-May 1999. Am. J. Infect. Control 27:520-532.
7. Chryssanthous, E. 2001. Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: comparison of the Etest and the Sensititre Yeast One Colorimetric Antifungal Panel with the NCCLS M27-A reference method. J. Clin. Microbiol. 39:4181-4183.
8. Collin, B., C. J. Clancy, and M. H. Nguyen. 1999. Antifungal resistance in non-albicans Candida species. Drug Resist. Update 3:9-14.
9. Colombo, A. L., M. Nucci, and R. Salomao. 1999. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn. Microbiol. Infect. Dis. 34:281-286.
10. Diekema, D. J., M. A. Pfaller, S. A. Messer, A. Houston, R. J. Hollis, G. V. Doern, R. N. Jones, and the SENTRY Participants Group. 1999. In vitro activities of BMS-207-147 against over 600 contemporary clinical blood stream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America. Antimicrob. Agents Chemother. 43:2236-2239.
11. Diekema, D. J., S. A. Messer, A. B. Brueggemann, S. L. Coffman, G. V. Doern, L. A. Herwaldt, and M. A. Pfaller. 2002. Epidemiology of candidemia: three-year results from the Emerging Infections and the Epidemiology of Iowa Organisms study. J. Clin. Microbiol. 40:1298-1302.
12. Edmond, M. B., S. E. Wallace, D. K. McClish, M. A. Pfaller, R. N. Jones, and R. P. Wenzel. 1999. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. 29:239-244.
13. Ellis, D., D. Marriott, R. A. Hajjeh, D. Warnock, W. Meyer, and R. Barton. 2000. Epidemiology: surveillance of fungal infections. Med. Mycol. 38(Suppl. 1):173-182.
14. Fridkin, S. K., and W. R. Jarvis. 1996. Epidemiology of nosocomial fungal infections. Clin. Microbiol. Rev. 9:499-511.
15. Grillot, R., O. Faure, J. Fruit, B. Sendid, P. Rispail, A. Datry, M. F. Biava, L. Kures, O. Morin, D. Toubas, S. Bretagne, B. Bouteille, B. Lebeau, S. Cassaing, B. Cuisenier, I. Grawey, J. L. Poirot, O. Eloy, C. Kauffmann-Lacroix, C. deChamps, G. Kac, V. Lavarde, M. Baixench, M. E. Bougnoux, L. Lachaud, C. Lamy, E. Pellet, C. Biodni, and the Groupe d'Etude des Mycoses Opportunistes. 2000. Working group: ECMM candidemia. ECMM prospective epidemiological survey of candidemia in Europe: report from France (682 cases). Rev. Iberoam. Micol. 17:S144.
16. Hunter, P. A., and D. S. Reeves. 2002. The current status of surveillance of resistance to antimicrobial agents: report on a meeting. J. Antimicrob. Chemother. 49:17-23.
17. Jones, R. N. 1996. The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance. Diagn. Microbiol. Infect. Dis. 25:53-61.
18. Jones, R. N. 2000. Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. J. Antimicrob. Chemother. 46(Topic T2):1-8.
19. Jones, R. N., and R. Masterton. 2001. Determining the value of antimicrobial surveillance programs. Diagn. Microbiol. Infect. Dis. 41:171-175.
20. Jones, R. N., and M. A. Pfaller. 1998. Bacterial resistance: a world-wide problem. Diagn. Microbiol. Infect. Dis. 31:379-388.
21. Kao, A. S., M. E. Brandt, W. R. Pruitt, L. A. Conn, B. A. Perkins, D. S. Stephens, W. S. Baughman, A. L. Reingold, G. A. Rothrock, M. A. Pfaller, R. W. Pinner, and R. A. Hajjeh. 1999. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin. Infect. Dis. 29:1164-1170.
22. Kauffman, C. A. 2001. Fungal infections in older adults. Clin. Infect. Dis. 33:550-555.
23. Kleinegger, C. L., S. R. Lockhart, K. Vargas, and D. R. Soll. 1996. Frequency, intensity, species, and strains of oral Candida vary as a function of age. J. Clin. Microbiol. 34:2246-2254.
24. Klepser, M. E. 2001. Antifungal resistance among Candida species. Pharmacotherapy 21:124S-132S.
25. Kossoff, E. H., E. S. Buescher, and G. M. Karlowicz. 1998. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr. Infect. Dis. J. 17:504-508.
26. Lamagni, T. L., B. G. Evans, M. Shigematsu, and E. M. Johnson. 2001. Emerging trends in the epidemiology of invasive mycoses in England and Wales. Epidemiol. Infect. 126:397-414.
27. Lewis, D. 2002. Antimicrobial resistance surveillance: methods will depend on objectives. J. Antimicrob. Chemother. 49:3-5.
28. Lockhart, S. R., S. Joly, K. Vargas, J. Swails-Wenger, L. Enger, and D. R. Soll. 1999. Defenses against oral Candida carriage break down in the elderly. J. Dent. Res. 78:857-868.
29. Masterton, R. G. 2000. Surveillance studies: how can they help the management of infection? J. Antimicrob. Chemother. 46(Topic T2):53-58.
30. McNeil, M. M., S. L. Nash, R. A. Hajjeh, M. A. Phelan, L. A. Conn, B. D. Plikalytis, and D. W. Warnock. 2001. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Infect. Dis. 33:641-647.
31. Meis, J., M. Petrou, J. Bille, D. Ellis, D. Gibbs, et al. 2000. A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagn. Microbiol. Infect. Dis. 36:215-223.
32. Morris, A. K., and R. G. Masterton. 2002. Antibiotic resistance surveillance: action for international studies. J. Antimicrob. Chemother. 49:7-10.
33. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A National Committee for Clinical Laboratory Standards, Wayne, Pa.
34. Nguyen, M. H., J. E. Peacock, Jr., A. J. Morris, D. C. Tanner, M. L. Nguyen, D. R. Snydman, M. M. Wagener, M. G. Rinaldi, and V. L. Yu. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
35. Peman, J., A. Cercos, M. C. Penalver, A. Viudes, E. Canton, A. Planes, E. Canes, A. del Palacio, J. Sevillano, J. Vinuelas, M. Ella, M. Gimernez, M. Pazo, J. J. Garcia, J. J. Palomar, J. M. Hernandez, E. Minguez, J. A. Martinez, Y. Fernandez, J. Martinez, C. Tapiol, M. S. Cuetara, and S. Giner. 2000. Epidemiological survey of candidemia in Spain. Rev. Iberoam. Micol. 17:S143.
36. Perea, S., J. L. Lopez-Ribot, W. R. Kirkpatrick, R. K. McAtee, R. A. Santillan, M. Martinez, D. Calabrese, D. Sanglard, and T. F. Patterson. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 45:2676-2684.
37. Pfaller, M. A. 1998. The epidemiology of invasive mycoses-narrowing the gap. Clin. Infect. Dis. 27:1148-1150.
38. Pfaller, M. A. 2001. The fungal pathogen shift in the United States. J. Crit. Illness 16(Suppl.):S35-S42.
39. Pfaller, M. A., S. A. Messer, A. Houston, M. S. Rangel-Frausto, T. Wiblin, H. M. Blumberg, J. E. Edwards, W. Jarvis, M. A. Martin, H. C. Neu, L. Saiman, J. E. Patterson, J. C. Dibb, C. M. Roldan, M. G. Rinaldi, and R. P. Wenzel. 1998. National Epidemiology of Mycoses Survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn. Microbiol. Infect. Dis. 31:289-296.
40. Pfaller, M. A., R. N. Jones, S. A. Messer, M. B. Edmond, and R. P. Wenzel. 1998. National surveillance of nosocomial bloodstream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn. Microbiol. Infect. Dis. 30:121-129.
41. Pfaller, M. A., R. N. Jones, G. V. Doern, H. S. Sader, R. J. Hollis, and S. A. Messer for the SENTRY Participant Group. 1998. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. J. Clin. Microbiol. 36:1886-1889.
42. Pfaller, M. A., R. N. Jones, G. V. Doern, A. C. Fluit, J. Verhoef, H. S. Sader, S. A. Messer, A. Houston, S. Coffman, and R. J. Hollis for the SENTRY Participant Group (Europe). 1999. International surveillance of bloodstream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn. Microbiol. Infect. Dis. 35:19-25.
43. Pfaller, M. A., R. N. Jones, G. V. Doern, H. S. Sader, S. A. Messer, A. Houston, S. Coffman, R. J. Hollis, and the SENTRY Participant Group. 2000. Bloodstream infections due to Candida species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998. Antimicrob. Agents Chemother. 44:747-751.
44. Pfaller, M. A., S. A. Messer, R. J. Hollis, and R. N. Jones. 2001. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob. Agents Chemother. 45:2862-2864.
45. Pfaller, M. A., D. J. Diekema, R. N. Jones, H. S. Sader, A. C. Fluit, R. J. Hollis, S. A. Messer, and the SENTRY Participant Group. 2001. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J. Clin. Microbiol. 39:3254-3259.
46. Pfaller, M. A., D. J. Diekema, R. N. Jones, S. A. Messer, R. J. Hollis, and the SENTRY Participant Group. 2002. Trends in antifungal susceptibility of Candida spp. from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 40:852-856.
47. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, and D. J. Diekema. 2002. In vitro activities of ravuconazole and voriconazole compared with those of four licensed systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46:1723-1727.
48. Rangel-Frausto, M. S., T. Wiblin, H. M. Blumberg, L. Saiman, J. Patterson, M. Rinaldi, M. Pfaller, J. E. Edwards, Jr., W. Jarvis, J. Dawson, and R. P. Wenzel. 1999. National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units. Clin. Infect. Dis. 29:253-258.
49. Rees, J. R., R. W. Pinner, R. A. Hajjeh, M. E. Brandt, and A. L. Reingold. 1998. The epidemiologic features of invasive mycotic infections in the San Francisco Bay Area, 1992-1993: results of a population-based laboratory active surveillance. Clin. Infect. Dis. 27:1138-1147.
50. Reeves, D. S. 2002. Antimicrobial resistance surveillance: current initiatives are not enough. J. Antimicrob. Chemother. 49:1.
51. Rennert, G., H. S. Rennert, S. Pitlik, R. Finkelstein, and R. Kitzes-Cohen. 2000. Epidemiology of candidemia - a nationwide survey in Israel. Infection 28:26-29.
52. Rex, J. H., T. J. Walsh, S. D. Sobel, S. G. Filler, P. G. Pappas, W. E. Dismukes, and J. E. Edwards. 2000. Practice guidelines for the treatment of candidiasis. Clin. Infect. Dis. 30:662-678.
53. Richards, M. J., J. R. Edwards, D. H. Culver, and R. P. Gaynes. 2000. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect. Control Hosp. Epidemiol. 21:510-515.
54. Richet, H. M. 2001. Better antimicrobial resistance surveillance efforts are needed. ASM News 67:304-309.
55. Ronveaux, O., B. Jans, and H. Carsauw. 1998. Epidemiology of nosocomial bloodstream infections in Belgium, 1992-1996. Eur. J. Clin. Microbiol. Infect. Dis. 10:695-700.
56. Saiman, L., E. Ludington, M. Pfaller, S. Rangel-Frausto, R. T. Wiblin, J. Dawson, H. M. Blumberg, J. E. Patterson, M. Rinaldi, J. E. Edwards, R. P. Wenzel, W. Jarvis, and the National Epidemiology of Mycosis Survey Study Group. 2000. Risk factors for candidemia in neonatal intensive care unit patients. Pediatr. Infect. Dis. J. 19:319-325.
57. Sandven, P. 2000. Epidemiology of candidemia. Rev. Iberoam. Micol. 17:73-81.
58. Sandven, P., L. Bevanger, A. Digranes, P. Gaustad, H. H. Haukland, and M. Steinbakk. 1998. Constant low rate of fungemia in Norway, 1991 to 1996. The Norwegian Yeast Study Group. J. Clin. Microbiol. 36:3455-3459.
59. Sheehan, D. J., C. A. Hitchcock, and C. M. Sibley. 1999. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12:40-79.
60. St-Germain, G., M. Laverdiere, R. Pelletier, A.-M. Bourgault, M. Libman, C. Lemieux, and G. Noel. 2001. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J. Clin. Microbiol. 39:949-953.
61. Tortorano, A. M., M. A. Viviani, A. L. Rigoni, E. Biraghi, M. Cogliati, A. Astolfi, C. Ossi, S. Perin, C. Bonaccorso, L. Garlaschi, G. Viola, M. Saudelli, S. Frugoni, A. Mauri, R. Passerini, C. Farina, M. Tejada, C. Cavanna, A. Raballo, A. Grossi, C. Bezzi, M. Spinelli, S. Bramati, G. Pinsi, L. Colombo, L. Ferrari, P. Troupioti, G. L. Lombardi, M. Arghittu, C. Agrapii, L. Sturla, G. Gialluca, M. G. Musmanno, A. Ceraminiello, P. Casella, R. Sala, S. Pierdomenico, S. Gualterotti, P. Porri, and A. Lizioli. 2000. ECMM survey of candidemia in Europe. Report from Italy. Rev. Iberoam. Micol. 17:S143.
62. Trick, W. E., S. K. Fridhin, J. R. Edwards, R. A. Hajjeh, R. P. Gaynes, and the National Nosocomial Infections Surveillance System Hospitals. 2002. Secular trend of hospital acquired candidemia among intensive care unit patients in the United States during 1998-1999. Clin. Infect. Dis. 35:627-630.
63. Viscoli, C., C. Girmenia, and A. Marinus. 1999. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin. Infect. Dis. 28:1071-1079.
64. Wey, S. B., M. Mori, M. A. Pfaller, R. F. Woolson, and R. P. Wenzel. 1988. Hospital acquired candidemia: attributable mortality and excess length of stay. Arch. Intern. Med. 148:2642-2645.
65. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
66. Yamamura, D. L., C. Rotstein, L. E. Nicolle, and S. Ioannou. 1999. Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992-1994. Fungal Disease Registry of the Canadian Infectious Disease Society. Can. Med. Assoc. J. 160:493-499.